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Abstract
A mismatch between optical power and ocular axial length results in refractive errors. Uncor-
rected refractive errors constitute the most common cause of vision loss and second leading
cause of blindness worldwide. Although the retina is known to play a critical role in regulating
ocular growth and refractive development, the precise factors and mechanisms involved are
poorly defined. We have previously identified a role for the secreted serine protease PRSS56
in ocular size determination and PRSS56 variants have been implicated in the etiology of
both hyperopia and myopia, highlighting its importance in refractive development. Here, we
use a combination of genetic mouse models to demonstrate that Prss56 mutations leading to
reduced ocular size and hyperopia act via a loss of function mechanism. Using a conditional
gene targeting strategy, we show that PRSS56 derived from Mu¨ller glia contributes to ocular
growth, implicating a new retinal cell type in ocular size determination. Importantly, we dem-
onstrate that persistent activity of PRSS56 is required during distinct developmental stages
spanning the pre- and post-eye opening periods to ensure optimal ocular growth. Thus, our
mouse data provide evidence for the existence of a molecule contributing to both the prenatal
and postnatal stages of human ocular growth. Finally, we demonstrate that genetic inactiva-
tion of Prss56 rescues axial elongation in a mouse model of myopia caused by a null mutation
in Egr1. Overall, our findings identify PRSS56 as a potential therapeutic target for modulating
ocular growth aimed at preventing or slowing down myopia, which is reaching epidemic
proportions.
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Author summary
Refractive errors mainly occur when changes in ocular size (ocular axial length) prevent
light from focusing directly on the retina. Myopia (nearsightedness) is the most common
form of refractive errors in which the focused image falls in front of the retina. The recent
unprecedented rise in the incidence of myopia has significant implications as individuals
with high myopia are at an increased risk of developing irreversible blinding conditions,
including retinal detachment, macular degeneration, and glaucoma. Ocular axial growth is
a key determinant of normal refractive development. Although the retina has been estab-
lished as a central player involved in the regulation of ocular growth, the specific retinal cell
type(s) and molecular pathways involved are poorly defined. Here, we have utilized genetic
mouse models to provide significant insight into spatial and temporal requirements of the
retinal factor PRSS56 in ocular size determination. Importantly, we have uncovered a pre-
viously unrecognized role for retinal Mu¨ller glia in ocular growth and demonstrated that
Prss56 inactivation has translational potential to rescue axial length elongation in a mouse
model of myopia. Collectively, our findings suggest that therapeutic strategies targeting
PRSS56 to modulate ocular growth could have important clinical implications to prevent
or slowdown the progression of myopia and associated blinding conditions in humans.
Introduction
A central feature of organogenesis is the intrinsic ability to faithfully determine final organ size
and shape. This is particularly important in the case of the eye where size determination is a
complex and tightly coordinated process critical for achieving optimal vision. During ocular
refractive development, precise ocular growth regulation is essential to ensure that the eye’s
axial length matches the optical focal plane, enabling focused images to fall on the retina
(emmetropization), resulting in clear vision. Alterations in ocular axial length constitute the
major cause of refractive errors. Shortened or elongated axial length result in focused images
falling behind or in front of the retina leading to hyperopia and myopia, respectively [1, 2].
Uncorrected refractive error is the most common cause of vision loss, and the second leading
cause of blindness after cataract [3]. Notably, the prevalence of myopia, the most common form
of refractive errors, is rising rapidly, reaching epidemic proportions in some countries [4–6].
This has significant public health implications as individuals with high myopia are at dispropor-
tionately increased risk of developing irreversible blinding conditions including retinal detach-
ment, myopic macular degeneration, cataract, and glaucoma [7]. Thus, there is an urgent need
to identify interventions offering the promise of modulating ocular growth, restoring healthy
refractive development, and preventing associated blinding conditions.
Although environmental factors have a strong influence in determining an individual’s
refractive status, genetic factors account for over 50% of the variability in refractive status within
populations [8–10]. Notably, mutations in genes involved in ocular size determination have
been implicated in a subset of refractive errors with a strong developmental basis (high myopia
and high hyperopia/nanophthalmos) [11–14]. More common forms of myopia are thought to
have a complex multifactorial etiology resulting from an intricate interplay between multiple
genetic and environmental factors [8, 9], and genome-wide association studies (GWAS) have
led to the identification of several genes/loci linked to myopia as well as those accounting for
natural variations in refraction in the general population [15, 16]. An improved understanding
of the contribution of individual genes, the pathways involved and their interactions will
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provide the necessary framework to define the mechanisms underlying refractive development
and associated errors, and identify potential targets for therapeutic intervention [5].
Ocular growth broadly comprises two distinct phases. In humans, the first phase occurs
prenatally and is primarily dictated by genetic factors [14], while the second phase takes place
postnatally and relies on a complex interplay between environmental and genetic factors [17].
Notably, postnatal ocular growth takes place when the eyes are developmentally open and is
highly dependent on visual experience, which modulates the rate of ocular growth. Consistent
with a requirement for patterned visual stimulation in ocular size determination, studies in
animal models have suggested an important role for retinal neurotransmitters and neuromo-
dulators in postnatal ocular growth and normal refractive development [18–20]. Signals ema-
nating from the retina are thought to be relayed to the sclera to promote remodeling of the
scleral extracellular matrix (ECM), a key step necessary to support ocular axial growth [21].
The use of genetically tractable animal models such as the mouse has recently gained popularity to
study ocular size determination and emmetropization [22]. The mouse eye responds to form deprivation
and lens defocus suggesting the existence of a functional emmetropization mechanism similar to that
operating in humans [22–24], and recent technological advances have allowed precise measurement of
refraction and ocular size in mice [25–27]. Importantly, studies in the mouse have guided the identifica-
tion and validation of genes, pathways and mechanisms involved in ocular growth, refractive develop-
ment and associated errors [22, 28–35]. For instance, mice with a null mutation of the transcriptional
factor Egr1 recapitulate the ocular axial length elongation and refractive shift characteristic of myopia and
constitute a useful animal model to dissect the mechanisms involved in ocular growth and myopia [31].
In addition, we have previously demonstrated that mice carrying a mutation in the gene coding for the
secreted trypsin-like serine protease PRSS56 (Prss56glcr4) exhibit reduced ocular size [36]. Mice homozy-
gous for thePrss56glcr4mutation have reduced ocular axial length, primarily caused by a decrease in poste-
rior segment size, without any gross morphological changes in ocular tissues [36]. Furthermore, we and
other groups have shown that PRSS56mutations lead to nanophthalmos (posterior microphthalmia) and
extreme hyperopia characterized by significant reduction in ocular axial length in humans [36–39]. Inter-
estingly, GWAS from multiple independent groups found an association between PRSS56 and myopia,
suggesting that common PRSS56 variants may also participate in the manifestation of more complex and
common forms of refractive errors [16, 40]. The implication of PRSS56 variants in both hyperopia and
myopia suggests a critical role for PRSS56 in ocular axial growth regulation and refractive development.
The availability of Prss56mutant mice exhibiting reduced ocular axial length and recapitulating hallmark
features of human nanophthalmos constitutes a unique resource to mechanistically dissect the molecular
pathways contributing to ocular size determination.
Here we have used a combination of genetic mouse models to perform a detailed molecular
and cellular characterization of the role of PRSS56 in ocular size determination. Our results estab-
lish a previously unknown role of Mu¨ller glia in the regulation of ocular axial growth and refractive
development. Significantly, we demonstrate a requirement for PRSS56 activity to support ocular
growth during distinct developmental stages spanning the pre- and post-eye opening periods, sug-
gesting that at least some molecules contribute to both the prenatal and postnatal stages of ocular
growth in humans. Importantly, we demonstrate that genetic inactivation of Prss56 can rescue
axial elongation in a mouse model of myopia caused by loss of EGR1 function.
Results
Loss of PRSS56 function contributes to ocular axial length reduction and hyperopia.
The Prss56 mutations we have previously identified in mice (ENU- induced mutation,
Prss56glcr4) and humans (c.1059_1066insC, p.Gln356Pro fsX152) give rise to a truncated pro-
tein lacking the C-terminal region, leaving the catalytic domain intact [36]. In agreement with
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the presence of a functional catalytic domain, we have previously demonstrated intact trypsin-
like serine protease activity of the recombinant PRSS56 mutant protein [36]. Similarly, human
PRSS56 mutations identified by independent groups are not predicted to completely disrupt
PRSS56 catalytic activity [37–39]. Thus, it is currently unknown whether PRSS56 mutations
causing ocular size reduction act via a loss or gain of function mechanism.
To determine if the reduction in ocular size observed in Prss56 mutant mice (Prss56glcr4/glcr4)
results from loss of PRSS56 function, we characterized the ocular phenotypes of a mouse strain
carrying a null allele of Prss56 (Prss56Cre also referred to as Prss56- in the manuscript). This
strain was generated by replacing exon1 of Prss56 with a sequence coding for CRE recombinase
resulting in a null allele and Prss56 promoter-driven CRE expression [41]. As the ocular size of
mice heterozygous for the Prss56Cre allele (Prss56+/-) was indistinguishable from that of their
wild-type littermates (S1A and S1B Fig), Prss56+/- mice were used as controls for most of our
experiments unless otherwise specified. Slit-lamp eye examination did not reveal any difference
between mice homozygous for the null allele (Prss56-/-) and control mice (Fig 1A). Next, we per-
formed a detailed ocular biometric analysis to assess various parameters, including axial length,
equatorial diameter, vitreous chamber depth (VCD), anterior chamber depth (ACD), and lens
thickness (as seen in OCT images, Fig 1B). Biometric analysis revealed reduced ocular size in
Prss56-/- mice, in which both ocular axial length and equatorial diameter were significantly
smaller compared to their Prss56+/- littermates at all ages examined (postnatal day (P) 15, P25
and P60) (Fig 1B–1D, S1C-S1G Fig). The VCD of Prss56-/- eyes was significantly smaller com-
pared to their Prss56+/- littermates (Fig 1E). Interestingly, the ACD was marginally larger in
Prss56-/- compared to control eyes (Fig 1E), and no significant difference was observed in lens
thickness (S1H Fig). These findings suggest that the reduction in post-equatorial segment pri-
marily accounts for the decreased ocular axial length observed in Prss56-/- mice. Consistent with
their reduced ocular axial length, Prss56-/- mice also exhibited hyperopic refraction (Fig 1F). In
addition, retinal thickness was increased in Prss56-/- eyes compared to control eyes (Figs 1G and
S1F). A detailed summary of ocular biometric measurements is presented in S1 Table. Together
these findings show that Prss56-/- mice have reduced ocular size, develop hyperopia, and recapit-
ulate the ocular phenotypes observed in the previously characterized ENU-induced Prss56glcr4
mutant mice [36], demonstrating that loss of PRSS56 function leads to reduced ocular size. We
next performed the ocular biometry (A- and B-scan) on an individual exhibiting nanophthal-
mos caused by a homozygous PRSS56 mutation (missense variant, p.G320R) [38]. Consistent
with ocular findings in Prss56-/- mice, the human PRSS56 mutation led to a substantial reduc-
tion in VCD compared to a normal emmetropic eye (Fig 1H and 1I and Table 1), suggesting
that PRSS56 mutations leading to nanophthalmos and extreme hyperopia in humans likely act
via a loss of function mechanism.
Prss56 ocular expression is restricted to the neural retina and is first detected in a pool
of late retinal progenitor cells. As a first step in addressing the role of PRSS56 in ocular size
determination, we performed a lineage tracing experiment to determine the identity and fate
of cells expressing Prss56 in the developing eye. To this end, Prss56Cre/+ mice expressing CRE
recombinase under the control of the Prss56 promoter were bred to the inducible R26tdTomato
reporter mice that express tdTomato in presence of CRE (Fig 2A). In the resulting offspring,
the tdTomato reporter gene will be expressed in Prss56-expressing cells and their derivatives,
thereby allowing lineage tracing. Assessment of tdTomato fluorescence on ocular sections
revealed that ocular Prss56 expression is restricted to the retina during both embryonic and
postnatal ages. Prss56 expression is first detected in sparse cells in the outer neuroblastic layer
(ONBL) at embryonic day (E) 16.5 (Fig 2B). The number of tdTomato positive retinal cells
increases over time as shown at E18.5 and P2 (Fig 2C and 2D). As the retina matures and cells
differentiate, intense tdTomato expression is detected in the inner nuclear layer (INL), and
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Fig 1. Prss56-/- eyes exhibit reduced ocular axial length and hyperopia. (A) Representative images of slit-lamp examination by broad-beam illumination to assess
ocular structures including the iris, pupil, and lens at 1 and 3 months of age. Prss56-/- eyes did not exhibit any obvious structural abnormalities and were
indistinguishable from Prss56+/- eyes. (B) Representative OCT images demonstrating a reduction in ocular size in Prss56-/- compared to Prss56+/- mice (shown are P30
eyes). The red, blue and yellow lines indicate ocular axial length (AL), vitreous chamber depth (VCD) and anterior chamber depth (ACD), respectively. (C-D) Prss56-/-
eyes exhibit a modest but highly significant reduction in axial length (C) and equatorial diameter (D) at P15 and P25. (E) A significant reduction in VCD and increase
in ACD was detected in Prss56-/- compared to Prss56+/- eyes (shown are data from P30 eyes). (F) Consistent with reduced ocular size, Prss56-/- mice display a
hyperopic refraction compared to Prss56+/- littermates (shown are data from 2-months old mice). (G) Retinal thickness was significantly increased in Prss56-/-
compared to Prss56+/- eyes. Values are presented as mean ± SD,  p<0.001, t-test. C and D: N> 10 per group; E and F: N 6 per group; and G: N 4. (H-I)
Representative B-scan images of eyes from an unaffected individual (H) and an individual with a PRSS56mutation (I). VCD is substantially reduced in the eye of the
individual carrying a mutant PRSS56 allele compared to a normal emmetropic eye.
https://doi.org/10.1371/journal.pgen.1007244.g001
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weaker signal in the photoreceptor layer (Fig 2E and 2F). Of note, tdTomato-positive cells are
enriched in the peripheral retina relative to the central retina (Figs 2F, S2A and S2C) and no
tdTomato signal was detected in other ocular tissues, including the sclera, choroid, cornea,
lens, ciliary body and iridocorneal angle (S2C and S2D Fig).
The spatio-temporal pattern of tdTomato labeling in the retina is suggestive of Prss56 being
expressed in late retinal progenitor cells (RPCs) and its derivatives. To confirm this, we per-
formed a series of immunolabeling studies. Supporting expression of Prss56 by RPCs, we show
that tdTomato positive cells express Ki67, a marker of dividing cells, in P0 retina (Fig 2G). In
addition, we found that tdTomato positive cells located in the INL express the Mu¨ller glia
markers vimentin and SOX2 (Figs S3A and 3A), as well as PKCα, a marker of bipolar cells (Fig
3B), demonstrating that tdTomato also labels late RPC derivatives. The reporter line used in
our experiments showed an inherent variability in tdTomato fluorescence intensity between
various retinal cell types. While intense tdTomato signal was detected in SOX2 and vimentin
immunopositive Mu¨ller cells, weaker tdTomato signal was observed in PKCα immunopositive
bipolar cells (Fig 3B, arrow). Using flow cytometry, we further demonstrate that Mu¨ller glial
cells (immunolabeled for glutamate synthetase (GS)) exhibit more intense tdTomato signal,
while rod photoreceptors (immunolabeled for Rhodopsin) exhibit weaker tdTomato signal
(Fig 3C). Together, these findings demonstrate that Prss56 is expressed in late RPCs fated to
give rise to subsets of rod photoreceptor, bipolar and Mu¨ller cells.
Prss56 expression is restricted to a subset of Mu¨ller glia following retinal cell differenti-
ation. The reporter (tdTomato) is not only expressed in cells actively transcribing Prss56 but
also in cells derived from parent cells expressing Prss56. Therefore, we performed in situ
hybridization to determine the expression pattern of Prss56 at critical time points during and
following complete maturation of retinal cells. We show that Prss56 expression is selectively
detected in the INL of the retina during (P10) and following (P15) maturation of retinal cell
types, and that Prss56 expression is enriched in the peripheral retina relative to the central ret-
ina (S3B and S3C Fig). Dual immunofluorescent labeling using antisense probes for GS (glial
cell marker) and Prss56, revealed colocalization of Prss56 (red) and GS (green) expression in
the INL of adult retina, while no signal was detected using the sense probes (Fig 4A). Interest-
ingly, in situ hybridization revealed a substantial increase in the number of Prss56 expressing
cells in Prss56 mutant retina (Prss56glcr4/glcr4, ENU- induced mutation with C-terminal trunca-
tion) compared to control retina (Prss56glcr4/+), suggesting increased Prss56 expression in
mutant retina (Fig 4A). Quantitative PCR analysis further demonstrated a significant upregu-
lation in the levels of Prss56 mRNA in mutant retina (Prss56glcr4/glcr4) compared to their control
counterparts from P15 onwards (Fig 4B). Collectively, these findings demonstrate that Prss56
is selectively expressed by a subset of Mu¨ller glia following retinal maturation, and suggest the
existence of a feedback regulatory loop modulating retinal Prss56 expression in response to
alteration in ocular size.
Early requirement for PRSS56 during ocular axial growth. Having demonstrated a role
for PRSS56 in ocular growth and its expression pattern during retinal development, we next
assessed the temporal requirement for PRSS56 activity during ocular size determination.
Table 1. Ocular biometry of an individual carrying a PRSS56 mutation.
Affected Right (mm) Affected Left (mm) Representative Normal (mm)
Anterior Chamber Depth (ACD) 1.76 1.53 2.82
Lens Thickness 4.20 4.30 4.04
Vitreous Cavity Depth (VCD) 9.36 9.64 15.52
Axial Length 15.32 15.47 22.18
https://doi.org/10.1371/journal.pgen.1007244.t001
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Using spectral-domain optical coherence tomography (SD-OCT), we detected a slight but sig-
nificant reduction in axial length in Prss56 mutant eyes compared to control eyes as early as P6
(Fig 5A). Moreover, Prss56 mutant retina was significantly thicker than control retina at P17
and 2 months (Figs 5B and S1F and S1 Table). Histological analysis of Prss56 mutant retina
Fig 2. Lineage tracing of Prss56 expressing cells during ocular development. (A) Prss56Cre/+ mice were crossed to R26tdTomato/+ reporter mice that express tdTomato
following CRE-mediated excision of a stop codon to label Prss56 expressing cells and their derivatives. (B-F) Representative images showing lineage tracing of Prss56
expressing cells (red) in Prss56Cre/+; R26tdTomato/+ eyes throughout ocular development. (B) tdTomato expression is first detected in the retina at embryonic day (E) 16.5
in retinal progenitor cells (RPCs). (C, D) The number of tdTomato positive RPCs increases with age, shown are (C) E18.5 and (D) P2 retinas. (E) By P7, when retinal
laminar organization is visible, tdTomato expression was predominantly observed in cells exhibiting characteristic features of Mu¨ller glia, with cell bodies located in the
inner nuclear layer and apicobasal processes extending across the retina. tdTomato expression was also detected in the inner segment of rod photoreceptors. (F)
tdTomato expression continues to be detected in Mu¨ller cells and rod photoreceptors following complete maturation of retinal cell types at P13. Interestingly,
tdTomato-labeled cells were enriched in the peripheral region and relatively sparser in the central region of the retina. (G) Ki67 immunolabeling of P0 Prss56Cre/+;
R26tdTomato/+ eyes demonstrate Ki67 expression in tdTomato positive retinal cells. E, embryonic day; GCL, ganglionic cell layer; INL, inner nuclear layer; ONBL, outer
neuroblastic layer; ONL, outer nuclear layer; P, postnatal day. Scale bars: 100μm (B-F) and 50μm (G).
https://doi.org/10.1371/journal.pgen.1007244.g002
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revealed no overt morphological defect with the exception of an increased number of nuclear
stacks in both the outer and inner nuclear layers, which could contribute to the observed
increase in retinal thickness (Fig 5C and 5D).
PRSS56 derived from Mu¨ller glia contributes to ocular axial growth. Ocular size reduc-
tion in Prss56 mutant mice is detected as early as P6 when a significant pool of undifferentiated
late RPCs is still present in the retina. Since Prss56 is expressed by late RPCs, it raises the
Fig 3. Earliest Prss56 expression occurs in late retinal progenitor cells. (A, B) Representative images of Prss56Cre/+; R26tdTomato/+ retina immunolabeled for SOX2
(A) or PKCα (B). (A) tdTomato expression (red) is present in SOX2 immunopositive Mu¨ller cells (green). The peripheral and central regions of the retina are
oriented left to right. (B) Representative images showing low tdTomato expression in a subset of PKCα immunolabeled bipolar cells in Prss56Cre/+; R26TdTomato/+
retina (arrows). (C) Flow cytometry analysis of Glutamine Synthetase (GS) and Rhodopsin expression in Prss56Cre/+; R26tdTomato/+ retinal cell suspensions. GS
expression was predominantly detected in tdTomato negative (green) and high tdTomato expressing cells (purple). Rhodopsin expression was predominantly
detected in tdTomato negative (green) and low tdTomato expressing (orange) cells. A minimum of 4 eyes per group was pooled for each retinal cell suspension and
flow cytometry analyses were repeated 2–3 times on independent samples. Gating was established based on Prss56Cre/+; R26tdTomato/+ retinal cell suspension incubated
with AlexaFluor 488 conjugated secondary antibody only. Together, these data demonstrate that Prss56 is expressed by late RPCs that give rise to bipolar cells, rod
photoreceptors, and Mu¨ller cells. Scale bars = 100μm(A) and 50μm (B).
https://doi.org/10.1371/journal.pgen.1007244.g003
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question of whether PRSS56 derived from either committed or differentiated Mu¨ller glia has
any role to play in ocular axial growth. To address this, we generated a conditional Prss56
mutant allele by flanking exons 2 to 4 with LoxP sites (Prss56F) that will give rise to a catalyti-
cally inactive PRSS56 protein following CRE-mediated excision (S4 Fig). Following validation
of the conditional allele (S5 Fig), we ablated Prss56 from Mu¨ller glia using the Rax-Cre ERT2
which specifically express CRE recombinase in Mu¨ller cells following tamoxifen induction
[42]. Selective inactivation of Prss56 in Mu¨ller glia was induced by tamoxifen injection at P8, a
time point preceding the developmental stage at which the majority of RPCs have differenti-
ated into their respective retinal cell types, including Mu¨ller cells (~ P10). Based on slit lamp
examination, eyes from tamoxifen-injected Prss56F/F; Rax-Cre ERT2 and control Prss56F/+;
Rax-Cre ERT2 mice were indistinguishable (Fig 6A). Ocular biometric analysis revealed a sig-
nificant reduction in ocular axial length and VCD and an increase in retinal thickness in
tamoxifen injected Prss56F/F; Rax-Cre ERT2 mice compared to both tamoxifen injected and
uninjected controls (Fig 6B–6E). Similar to what we observed in the Prss56glcr4/glcr4 retina, we
detected a significant upregulation of retinal Prss56 mRNA levels following conditional abla-
tion of Prss56 from Mu¨ller glia compared to control eyes (Fig 6F). These findings suggest that
PRSS56 derived from differentiated Mu¨ller cells contributes to ocular axial growth.
Next, we assessed if loss of PRSS56 function affects the structural or morphological orga-
nization of Mu¨ller glia. To this end, we took advantage of our Prss56Cre; R26tdTomato reporter
line, which specifically labels the subset of Mu¨ller glia derived from Prss56-expressing RPCs
and performed a morphological analysis of retinal sections and whole-mounts at P6. This
specific time point was selected for three main reasons: 1) it corresponds to the develop-
mental time point when Mu¨ller glia committed progenitors begin to express markers of
mature Mu¨ller glia [43], 2) it marks the initiation of endfeet formation and precedes com-
plex endfeet elaboration in the inner limiting membrane (ILM) [44], and 3) it coincides
Fig 4. Prss56 is predominantly expressed by a subset of Mu¨ller cells. (A) Dual fluorescent in situ hybridization for Prss56 (red) and Glutamine Synthetase (GS, green)
showed localization of Prss56 expression in the inner nuclear layer of the retina from adult Prss56glcr4/+ and Prss56glcr4/glcr4 mice (2 months old). Prss56 expression
colocalized with that of GS, a marker of Mu¨ller cells. Both the signal intensity and number of Mu¨ller glia expressing Prss56 were substantially higher in Prss56glcr4/glcr4
compared to Prss56glcr4/+ retina, indicating increased Prss56 expression in Prss56 mutant retina. (B) Graph showing relative expression of Prss56 mRNA levels using
qPCR in wild-type and mutant retina at different developmental stages. Increased Prss56 expression was detected in the mutant retina from P15 onward. Prss56
expression was normalized to the expression of three housekeeping genes (Hprt1, Actb1 and Mapk1). Data are presented as fold expression relative to wild-type
(mean ± SEM), N4 /group.  p<0.001, t-test. Scale bars= 100μm and 50μm for low and high magnification images in A.
https://doi.org/10.1371/journal.pgen.1007244.g004
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with the time point at which ocular size reduction is first detected in Prss56 mutant mice.
Although we did not observe any gross change in the spatial arrangement of Mu¨ller glia in
Prss56 mutant retina (S3C Fig), we detected subtle alterations in the organization of Mu¨ller
glia endfeet in P6 retinal sections and whole mounts (Fig 6G and 6H). We found that the
proportion of tdTomato positive Mu¨ller glia endfeet exhibiting a more elaborate morphol-
ogy was significantly greater in Prss56 mutant compared to control retinal whole mounts
(59.26 ± 8.04% in mutant vs 22.72 ± 5.33% in control, p<0.001). These findings suggest pre-
mature branching and maturation of Mu¨ller glia endfeet in Prss56 mutant mice and raise
the possibility that altered structural organization of Mu¨ller glia may contribute to the ocu-
lar size reduction observed in Prss56 mutant mice (Fig 6G–6I).
Fig 5. Early requirement for PRSS56 in ocular size determination. (A, B) Ocular biometric analysis by OCT
revealed reduced ocular axial length (A) and increased retinal thickness (B) in Prss56glcr4/glcr4 eyes compared to
Prss56glcr4/+ eyes at distinct developmental time points ranging from P6 to P17. Although both mutant and control
mice exhibit an age-dependent increase in ocular size, ocular axial length is significantly reduced in Prss56 mutant
mice compared to control mice. The reduction in ocular axial length was detected as early as P6 (A). (B) OCT analysis
revealed that Prss56 mutant retina is significantly thicker than control retina (shown is P17). (C-D) Histological
analysis revealed that the number of nuclear stacks in both the inner and outer retinal nuclear layers (INL and ONL,
respectively) was consistently greater in the Prss56 mutant retina (D) compared to control retina (C). For comparison
between Prss56 mutant and control mice: p<0.05,  p<0.01,  p<0.001, t-test. Scale bars = 100μm. Values are
presented as mean ± SD. N 12 per group for P6 measurements and N> 6 for P8 and P17 (A, B).
https://doi.org/10.1371/journal.pgen.1007244.g005
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Fig 6. Conditional RAX-Cre-mediated ablation of Prss56 from fully differentiated Mu¨ller glia leads to ocular size reduction. Prss56 was conditionally ablated from
Mu¨ller cells in a time-specific manner by crossing Prss56F/F to the inducible RAX-Cre mouse strain (Rax-CreERT2). CRE expression was induced by tamoxifen injection at
P8, a time point preceding complete Mu¨ller glia differentiation. (A) Representative images of slit lamp examination by broad-beam illumination following tamoxifen
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Sustained PRSS56 activity is required for ocular axial growth. Our results show that
Prss56 is actively expressed in both the developing and adult retina, raising the possibility that
PRSS56 might regulate ocular growth during distinct development stages spanning the pre and
post-eye opening periods. To determine the temporal requirements of PRSS56 in modulating
ocular axial growth, we bred conditional Prss56 mutant mice to the inducible ubiquitous Ubc-
Cre line to ablate Prss56 at distinct stages of ocular development. Unlike the human eye, the
mouse eye remains closed during the early postnatal period until the eyelids open around P13
(Fig 7A). Therefore, in this regard, postnatal time points preceding P13 in the mouse are analo-
gous to late prenatal stages of human ocular growth when the eyes are closed. Mice carrying the
Prss56F allele and the inducible Ubc-Cre transgene (Prss56F/F; Ubc-Cre ERT2 and control: Prss56F/
+; Ubc-Cre ERT2) were injected with tamoxifen at P6 or P8 (stages at which the eyes are closed)
and compared to uninjected and injected control groups. Ablation of Prss56 at both time points
caused a significant decrease in ocular axial length and VCD compared to control groups (mea-
sured at P17; Fig 7B–7D). Administration of tamoxifen at P6 caused a greater reduction in ocu-
lar axial length (compare P6 to P8 in Fig 7B), suggesting a continuous requirement for PRSS56
activity during ocular growth. Next, we injected tamoxifen at P13 to determine whether PRSS56
function is required after eye opening. Ablation of Prss56 following tamoxifen injection at P13
caused a modest but significant decrease in ocular axial length compared to control groups
(measured at P30 and P45, Fig 7E). The decrease in ocular size was accompanied by a significant
decrease in VCD and increase in retinal thickness (Fig 7F and 7G).
To test for a potential role of PRSS56 at stages when eyes are responsive to patterned visual
stimulation [45], we injected Prss56F/F; Ubc-Cre ERT2 and control mice (Prss56F/+; Ubc-Cre
ERT2) with tamoxifen at P18 and performed ocular biometry at 3 different time points (P30,
P45, and P60). Although the axial length of Prss56F/F; Ubc-Cre ERT2 eyes tended to be slightly
shorter compared to that of control eyes, the difference was not statistically significant at any
of the ages examined (P = 0.056 at P60 measurement, Fig 7H). In contrast, a significant
decrease in VCD was detected in Prss56F/F; Ubc-Cre ERT2 eyes compared to control eyes at all
ages examined (Fig 7J). Notably, the decrease in VCD following conditional Prss56 ablation
was progressive and age-dependent. Since we did not observe a significant reduction in ocular
axial length, we also measured other ocular layers contributing to ocular axial length, including
the lens and anterior chamber. While the lens thickness was comparable between the Prss56
ablated and control eyes (S6A Fig), the ACD was marginally increased following Prss56 abla-
tion (S6B Fig), adding to the difficulty of detecting small changes in ocular axial length. Addi-
tionally, we assessed ocular refraction at 3 months of age following tamoxifen injection at P18
and found that Prss56F/F; Ubc-Cre ERT2 mice are hyperopic compared to control mice (Fig
7M). Furthermore, a significant upregulation of retinal Prss56 mRNA levels was also observed
following tamoxifen injection at P13 and P18 (Fig 7L). A detailed summary of ocular biometric
injection at P8. Prss56F/F; Rax-CreERT2 eyes were indistinguishable from control Prss56F/+; Rax-CreERT2 eyes at 2 months of age. (B, C) Following tamoxifen injection
(TAM +; horizontal axis) at P8, Prss56F/FRax-CreERT2 mice display a significant decrease in ocular axial length (B) and increase in retinal thickness (C) compared to
control eyes (Prss56F/+; Rax-CreERT2 or Prss56F/F mice without Rax-CreERT2), N = 6 to 8 per group. (D) Following tamoxifen injection at P8, a significant reduction in VCD
was detected in Prss56F/F; Rax-CreERT2 eyes compared to control Prss56F/+; Rax-CreERT2 eyes, N = 6 per group. Ocular axial length, retinal thickness, and VCD in
uninjected Prss56F/F; Rax-CreERT2 and Prss56F/+; Rax-CreERT2 mice were indistinguishable. (E) Representative OCT images showing reduced axial length and VCD in
Prss56F/F; Rax-CreERT2 eyes compared to the control Prss56F/+; Rax-CreERT2 or Prss56F/F mice. (F) qPCR analysis following tamoxifen injection at P8 revealed that Prss56
mRNA was significantly upregulated in Prss56F/F ; Rax-CreERT2 retina compared to their Prss56F/+ ; Rax-CreERT2 counterparts or uninjected controls, N 6 per group.
Values are presented as mean ±SD;  p<0.05,  p<0.01,  p<0.001, t-test. (G-I) Mu¨ller glia endfeet organization of Prss56Cre; R26tdTomato reporter mice during retinal
development. Representative images of retinal section (G, I) or whole mount (H) showing Mu¨ller glia endfeet from control and Prss56 mutant mice at P6. (I) Magnified
images of the retinal endfeet are shown. The ILM of Prss56 mutant mice (Prss56Cre/gclr4; R26tdTomato) at P6 is marked by regions of increased endfeet complexity (arrow
head) compared to the ILM of control mice (Prss56Cre/+; R26tdTomato). A substantial proportion of endfeet appear more spread out, occupying a larger area in the mutant
compared to control retinal whole mounts (occupying smaller area). Red boxes highlight individual endfoot. N = 4 per genotype and scale bars = 17μm in G and I, and
50μm in H. ACD, anterior chamber depth; AL, axial length; VCD, vitreous chamber depth.
https://doi.org/10.1371/journal.pgen.1007244.g006
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measurements, sample size, and statistical significance following conditional ablation of Prss56
using Rax-Cre and Ubc-Cre is presented in S2 Table. Collectively, our findings indicate that
sustained PRSS56 activity is required throughout distinct stages of ocular development to reg-
ulate axial growth. Significantly, they demonstrate that PRSS56 is a molecular factor that oper-
ates during both the pre- and post-eye opening developmental stages of ocular axial growth.
Genetic inactivation of PRSS56 rescues ocular axial elongation in a mouse model of
myopia. Our data shows that lack of PRSS56 activity cause ocular size reduction. To explore
the translational potential of this finding, we tested the hypothesis that inactivation of
PRSS56-mediated pathway(s) could slowdown axial elongation linked to myopia. To this end,
we performed a genetic study to determine the effect of Prss56 ablation in a mouse model of
myopia caused by a null mutation in Egr1. EGR1 is a known regulator of ocular axial growth,
and Egr1 expression is up- or down-regulated in animal models with experimentally-induced
reduction or increase in ocular axial length, respectively [46, 47] Importantly, mice lacking
EGR1 (Egr1-/-) recapitulate the characteristic hallmarks of myopia including increased ocular
axial length and a myopic refractive shift [31]. Because ocular biometric parameters were
indistinguishable between Prss56+/-; Egr1+/- and Prss56+/+; Egr1+/+ mice, we used Prss56+/-;
Egr1+/- mice as controls for our experiments (S7 Fig). The ocular axial elongation resulting
from Egr1 deficiency was detected as early as P10, but was more prominent at later time points
(compare Prss56+/-; Egr1-/- to Prss56+/-; Egr1+/—mice, Fig 8A and 8B). Importantly, a concomi-
tant increase in VCD, but no significant change in retinal thickness was observed at all ages
examined in Egr1 deficient mice compared to control mice (Fig 8D and 8E). As expected,
Prss56 mutant eyes (Prss56-/-; Egr1+/-) exhibit a significant reduction in axial length and VCD
compared to control eyes (Prss56+/-; Egr1+/-, Fig 8B–8D). Interestingly, the axial length and
VCD of double mutant (Prss56-/-; Egr1-/-) eyes were not significantly different from that of the
control eyes, (Fig 8A, 8B and 8D). Consistent with our ocular size findings, refraction was sig-
nificantly rescued in double mutants compared to single Egr1 or Prss56 mutants, exhibiting
myopia or hyperopia, respectively (Fig 8C). Interestingly, despite the ocular axial length of
double mutants being comparable to that of control mice, they exhibit a significantly thicker
Fig 7. PRSS56 activity is required during both the vision-independent and dependent stages of ocular growth. To
determine the temporal window critical for the PRSS56-mediated effect on ocular axial growth, Prss56 conditional
mutant mice (Prss56F/F) were crossed to mice expressing the ubiquitous inducible Ubc-Cre recombinase (Ubc-
CreERT2). (A) Schematic of tamoxifen treatment at distinct developmental stages preceding and following the opening
of the eyes. Tamoxifen injection at two different time points, P6 and P8, was performed to ablate Prss56 after the
earliest detectable effect of mutant Prss56 on ocular axial length. (B-D) OCT-based ocular biometry demonstrates that
following tamoxifen injection, Prss56F/F; Ubc-CreERT2 mice display a significantly reduced ocular axial length (B) and
increased retinal thickness (C) and a significant decrease in VCD (D) compared to the control Prss56F/+; Ubc-CreERT2
mice (measured at P17). The ocular axial length, retinal thickness, and VCD of uninjected Prss56F/F; Ubc-CreERT2 and
Prss56F/+; Ubc-CreERT2 mice were indistinguishable. Administration of tamoxifen at P6 caused a greater decrease in
ocular axial length compared to administration at P8 suggesting a requirement for continuous PRSS56 activity during
ocular development to sustain normal ocular growth, N = 6 to 8 per group for A and B. (E-G) OCT measurements
demonstrate that following tamoxifen injection at P13 (a time point when the eyes are open), Prss56F/F; Ubc-CreERT2
mice display a slight but significant decrease in ocular axial length (E) and increase in retinal thickness (F) at P30 and
P45. Reduced ocular axial length was associated with a significant decrease in VCD in Prss56F/F; Ubc-CreERT2 mice
compared to Prss56F/+; Ubc-CreERT2 and uninjected controls at P30 and P45, N = 5 to 10 per group (G). (H-J) Ocular
biometry following tamoxifen injection at the beginning of a critical emmetropization period (P18) shows that the
ocular axial length is not significantly different between the Prss56F/F; Ubc-CreERT2 and control mice at any of the three
ages examined (P30, P45, and P60). However, Prss56F/F; Ubc-CreERT2 mice display a slightly thicker retina and
significantly reduced VCD compared to the control groups. (K) Following Prss56 ablation at P13 and P18, the eyes
display a decrease in the combined value of retinal thickness and VCD. (L) qPCR analysis revealed elevated Prss56
mRNA levels in Prss56F/F; Ubc-CreERT2 retina compared to Prss56F/+; Ubc-CreERT2 retina following tamoxifen injection
at P8, P13, or P18 (shown are data from mice harvested at P17 and P60, respectively). (M) Following Prss56 ablation at
P18, the eyes display a hyperopic shift in refraction compared to control eyes at 3 months (N = 6 per group). Values are
presented as mean ± SD (or mean ± SEM in L);  p<0.05,  p<0.01,  p<0.001, t-test.
https://doi.org/10.1371/journal.pgen.1007244.g007
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Fig 8. Prss56 ablation rescues myopia in mice. (A) Representative OCT images demonstrating that Prss56 ablation rescues myopia in Egr1-/- mice (compare Prss56+/-;
Egr1-/- to Prss56-/-;Egr1-/-, shown are P30 eyes). Reciprocally, Egr1 deficiency rescues hyperopia in Prss56-/- mice (compare Prss56-/-;Egr1+/- to Prss56-/-;Egr1-/-). The red
and blue lines indicate ocular axial length (AL) and vitreous chamber depth (VCD), respectively. (B) Prss56-/-;Egr1+/- eyes display a significant reduction in axial
length, whereas Prss56+/-;Egr1-/- exhibit significantly elongated axial length compared to the control eyes (Prss56+/-;Egr1+/- ). The eyes of double mutants (Prss56-/-;
Egr1-/-) attain a size that is not significantly different from control eyes (Prss56+/-;Egr-/-), at all ages examined (P10 to P60). (C) Consistent with modulation of ocular
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retina, similar to what is observed in Prss56 single mutant eyes (Fig 8E). A detailed summary
of ocular biometric measurements from Egr1 and Prss56 single and double mutants, sample
size, and their statistical significance are presented in S3 Table. These findings show that
Prss56 inactivation rescues axial elongation/myopia resulting from EGR1 deficiency.
Discussion
The molecular and cellular mechanisms involved in ocular size regulation and refractive devel-
opment are poorly understood. Here, we have used a combination of genetic mouse models to
elucidate the role of PRSS56 in ocular axial growth. We show that loss of PRSS56 function
causes ocular axial length reduction and hyperopia. Moreover, utilizing a lineage tracing strat-
egy and a combination of molecular approaches, we demonstrate that Prss56 ocular expression
is first detected in a pool of late RPCs and then in a subset of Mu¨ller glia following retinal cell
differentiation. Importantly, our findings demonstrate that PRSS56 derived from Mu¨ller glia
contributes to ocular axial length elongation, uncovering a previously unrecognized role for
Mu¨ller glia in ocular growth. Furthermore, we show that continuous PRSS56 activity is
required to sustain ocular growth throughout distinct stages of ocular development spanning
the pre- and post-eye opening periods. Thus, findings from our mouse models suggest that at
least some of the factors guiding ocular growth are conserved across the prenatal and postnatal
stages of ocular development.
Impaired processing of PRSS56’s endogenous substrate(s) potentially contributes to
ocular size reduction. Using mice homozygous for a null allele of Prss56, we demonstrate
that loss of PRSS56 function causes a reduction in ocular size and hyperopia (Fig 1A–1F), sug-
gesting that impaired processing of PRSS56 protease’s endogenous substrate(s) may underlie
ocular size reduction. Since the loss of PRSS56 function leads to reduced ocular size, PRSS56
variants associated with myopia (identified by GWAS) likely act in an opposite manner, i.e. via
a gain of function mechanism, to induce ocular axial elongation [16, 40, 48]. Our current
efforts are geared towards identifying PRSS56 endogenous substrates to gain further mecha-
nistic insight into factors contributing to ocular growth.
Identification of a novel subpopulation of Mu¨ller glia. Our results demonstrate that
Prss56 ocular expression is first detected embryonically in a pool of late RPCs and later in
Mu¨ller glia following retinal cell differentiation (Figs 2 and 3). Mu¨ller glia has traditionally
been viewed as a homogeneous cell population. Although previous studies have reported het-
erogeneity in gene expression among individual Mu¨ller cells, evidence supporting Mu¨ller glia
being a heterogeneous group of cells is very limited [49, 50]. Here, we have identified a unique
subset of Mu¨ller glia that expresses Prss56 and are enriched in the peripheral region of the ret-
ina (Figs 2, S3B and S3C). It is tempting to speculate that the heterogeneity in the molecular
profile and distribution of Mu¨ller cells may have evolved to support their diverse retinal
functions.
Modulation of Prss56 expression in response to mutations in gene(s) involved in ocular
size determination. Our study demonstrates that retinal expression of Prss56 is significantly
increased in response to loss of PRSS56 function (observed both in Prss56glcr4/glcr4 mice or
axial length by Prss56 and Egr1 mutations, hyperopic refraction observed in Prss56-/-;Egr1+/- eyes was rescued in the double mutants (Prss56-/-;Egr1-/-). Conversely,
Prss56 ablation rescued myopic refraction observed in Prss56+/-;Egr1-/- eyes (compare Prss56+/-;Egr1-/- to Prss56-/-;Egr1-/-, shown are data from 2-months old mice). (D)
The VCD of double mutant eyes (Prss56-/-;Egr1-/-) was significantly reduced compared to Egr1 single mutant eyes (Prss56+/-;Egr1-/-) and increased compared to Prss56
single mutant eyes (Prss56-/-;Egr1+/-). The VCD of double mutant eyes was not significantly different from the control eyes. (E) The retina is thicker in double mutants
(Prss56-/-;Egr1-/-) compared to control mice (Prss56+/-;Egr1+/-) at P30 and P60, despite their ocular axial length being similar. Values are presented as mean ± SD. For
comparison between single mutant and controls:  p<0.05;  p<0.01; p<0.001, t-test. For comparison between single mutant and double mutants: # p<0.05; ##
p<0.01; ###p<0.001, t-test. B-D: N 6 per group; E: N 8 per group.
https://doi.org/10.1371/journal.pgen.1007244.g008
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following conditional Prss56 ablation, Figs 4A and 4B, 6F and 7L). Interestingly, retinal expres-
sion of Prss56 is also upregulated in Mfrpmutant mice [51]. Mutations in the gene coding for
MFRP, a frizzled-related protein expressed in the retinal pigment epithelium (RPE), cause
nanophthalmos in humans, a phenotype similar to that resulting from PRSS56 mutations [13].
These findings suggest that modulation of Prss56 expression levels may have evolved as part of
a feedback regulatory mechanism aimed at overcoming alterations in ocular growth resulting
from disruption of genes/pathways involved in refractive development.
Identification of a novel role of Mu¨ller glia in ocular axial growth. In this study, we
used conditional Prss56 mutant mice to demonstrate that PRSS56 derived from differentiated
Mu¨ller glia contributes to ocular axial growth (Fig 6A–6F). However, ocular size reduction in
Prss56 mutant mice is detected before complete differentiation of Mu¨ller glia, suggesting that
both glial committed progenitor cells and differentiated Mu¨ller cells constitute important
sources of PRSS56 to support ocular growth. Being a secreted protease, PRSS56 could modu-
late the extracellular milieu of the retina by processing its endogenous substrate(s), such as ret-
inal or neighboring ECM components or cell surface receptors. Notably, PRSS56 was recently
shown to be localized in the retinal ILM (the retinal basement membrane) [52]. Thus, it is pos-
sible that loss of PRSS56 activity could alter the composition of the ILM, which in turn could
lead to the premature elaboration of Mu¨ller glia endfeet observed in Prss56 mutant retina (Fig
6G–6I). Defective ILM has been linked to abnormal ocular growth and mutations in genes
encoding ECM proteins present in the ILM have been implicated in axial elongation and myo-
pia [53]. Henceforth, the ILM has been proposed as a critical structure providing the mechani-
cal strength regulating the pressure within the vitreous chamber, which is subsequently
transferred to the sclera of the developing eye to modulate ocular growth [53]. It is tempting to
speculate that failure to generate sufficient tension due to altered ILM composition may
underlie ocular size reduction resulting from loss of PRSS56 function. Alternatively, as
reduced VCD was the most conspicuous ocular manifestation detected in mice and a patient
with mutant PRSS56 (Fig 1E and 1I), a failure to maintain normal vitreous volume may
account for the altered ocular axial length. Mu¨ller glial cells have been suggested to be impor-
tant regulators of intraretinal water flow into the vitreous cavity [54–56]. Thus, another possi-
ble mechanism by which loss of PRSS56 function may contribute to ocular size reduction is by
failure to regulate fluid flow and maintain normal vitreous volume.
Findings from our mouse study suggest a role for PRSS56 in pre- and post-natal human
ocular growth. Our results suggest that continuous PRSS56 activity is required for normal
ocular growth. Developmental stages preceding and following eye opening in the mouse are
analogous to the prenatal and postnatal stages (when the eyes are exposed to visual experience)
of human ocular growth, respectively. Thus, the impact of PRSS56 mutations on human ocular
growth is likely to begin prenatally before patterned visual activity modulates the rate of ocular
growth. These findings are in agreement with previous suggestions that genetic alterations
leading to nanophthalmos interfere with prenatal ocular growth [14]. Importantly, ablation of
Prss56 following eye opening in the mouse (tamoxifen injection at P13 and P18) resulted in a
modest reduction in ocular dimension and a hyperopic shift in refraction (Fig 7E, 7J and 7M),
suggesting that the role of PRSS56 in ocular growth regulation may extend beyond the prenatal
developmental window in humans. These findings establish that persistent PRSS56 activity is
required during distinct stages of ocular development to support ocular growth and normal
refractive development. Although, visual input plays a critical role in the regulation of postna-
tal ocular growth, both vision-adjusted and unadjusted ocular growth are likely to operate in
concert to determine ocular size [17, 57]. Here, we have discovered that PRSS56 contributes to
ocular growth during a window when the eyes are subject to patterned visual stimulation (Fig
7E–7J). The specific contribution of PRSS56 in vision-adjusted ocular growth, if any, is yet to
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be determined. However, it is plausible that the fundamental processes controlling ocular
growth are conserved throughout the various stages of ocular development [17], with an addi-
tional level of regulation during the vision-adjusted phase where the rate of ocular growth is
dependent on the refractive status of the eye. Future studies aimed at investigating the specific
role of PRSS56 in emmetropization will utilize experimental paradigms to examine the effect
of stage-specific ablation of Prss56 on vision-guided ocular growth.
Identification of PRSS56 as a potential target for therapeutic intervention to slowdown
myopia progression. The most common forms of myopia result from aberrant postnatal
ocular growth. Given the role of PRSS56 in supporting ocular growth at stages following open-
ing of the eyelid, targeting PRSS56 appears a viable therapeutic strategy to slowdown axial
elongation underlying myopia. Our genetic experiment suggests that opposing effects of
Prss56 and Egr1 mutations are canceled in double mutant animals, causing their eyes to attain
a size that is indistinguishable from that of control eyes. Thus, it is likely that parallel reciprocal
pathways driven by PRSS56 and EGR1 regulate ocular axial growth. Interestingly, EGR1 is
detected in cells of the retinal INL, including amacrine cells [47], raising the possibility that
PRSS56 and EGR1 may act through two different retinal cell types to regulate ocular size.
Overall, these results demonstrate that Prss56 inactivation rescues axial elongation/myopia
resulting from EGR1 deficiency, and thereby establish PRSS56 as a potential therapeutic target
for interventions aimed at preventing myopia.
In summary, we demonstrate that loss of PRSS56 function leads to ocular size reduction
and hyperopia and identify a novel role for Mu¨ller glia in ocular axial growth. Future studies
will aim at determining whether PRSS56 regulate ocular growth by directly influencing Mu¨ller
glia function. Our findings also show that PRSS56 activity is required at distinct developmental
stages spanning the pre- and post-eye opening periods. To the best of our knowledge, this is
the first study documenting the existence of a genetic factor whose activity is required continu-
ously through various stages of ocular development to support normal refractive development.
Finally, we demonstrate that Prss56 inactivation rescues axial elongation in a mouse model of
myopia. Since PRSS56 variants have been implicated in both human hyperopia and myopia,
our findings have direct relevance to human ocular refractive development. Given the steep
rise in the prevalence of myopia, there is an urgent public health need to identify therapeutic
targets to prevent or slow down myopia. This study demonstrates that interventions aimed at
regulating PRSS56 activity have the potential to modulate ocular growth, restore healthy
refractive development and prevent associated blinding conditions.
Methods
Ethics statement
All experiments were conducted in accordance with the Association for Research in Vision
and Ophthalmology’s statement on the use of animals in ophthalmic research. Mouse studies
were performed in compliance with protocols approved by the Institutional Animal Care and
Use Committee at University of California San Francisco (Approval numbers: AN153083 and
AN120008). Animals were given access to food and water ad libitum and housed under con-
trolled conditions including a 12-h light/dark cycle in accordance with the National Institutes
of Health guidelines. For some of the experiments mice were anesthetized with ketamine/xyla-
zine (100 mg/kg and 5mg/kg, respectively).
Mouse lines
Mutant mice. Prss56glcr4: C57BL/6.Cg-Prss56 glcr4/SjJ: Mice carrying ENU induced muta-
tion in Prss56, causing truncation of PRSS56 C–terminal region [36].
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Prss56 targeted mutation (Prss56Cre): C57BL/6.Cg-Prss56tm(cre), Prss56 exon1 was replaced
by a sequence coding for CRE recombinase to generate a null mutation [41]. Prss56 condi-
tional mutation (Prss56F): C57BL/6.Cg-Prss56tm1/SjJ, mice carrying LoxP sites flanking exons
2 to 4 of Prss56. Excision of the LoxP sites results in a catalytically inactive form of PRSS56.
Egr1 mutant mice: C57BL/6.Egr1tm1Jmi/J, the targeted mutation by insertion of a PGK-neo
cassette introduces stop codon resulting in protein truncation upstream of the DNA-binding
domain [58].
Reporter line. Gt(ROSA)26Sortm14(CAG-tdTomato)Hze : Cre reporter mice harbor a LoxP-
flanked STOP cassette preventing transcription of a CAG promoter-driven tdTomato [59].
The targeted mutation was inserted into the Gt(ROSA)26Sor locus. TdTomato expression is
dependent on the presence of CRE recombinase.
Cre lines. 1) Rax-Cre ERT2: Raxtm1.1(cre/ERT2)Sbls/J mice express tamoxifen-inducible CRE
recombinase under the control of the Rax promoter [42].
2) Ubc-Cre ERT2: C57BL/6.Cg-Tg(UBC-Cre/ERT2)1Ejb, Cre-ERT2 transgenic mouse line was
generated carrying a human ubiquitin C (UBC) promoter sequence upstream of a Cre-
ERT2 fusion gene [60].
3) Sox2-Cre:Tg(Sox2-cre)1Amc/J: Sox2-Cre transgenic mice express CRE recombinase under
the control of the mouse Sox2 promoter expressed as early as E6.5 (ubiquitous Cre line)
[61].
No gender effect has been observed on ocular size reduction resulting from Prss56 mutations
in our previous and current studies. Both males and females were included in all experiments
described in this manuscript. For most experiments, littermates were used for comparisons
between genotypes. PCR genotyping was performed on genomic DNA obtained from tail
biopsies digested with Proteinase K (Sigma, St. Louis, MO, USA) using the primers indicated
in S4 Table.
Clinical slit lamp examination
Ocular anterior segment examinations were performed on 1–5 months old mutant mice and
control littermates using a slit lamp biomicroscope (Topcon SL-D7; Topcon Medical Systems,
Oakland, NJ, USA) attached to a digital SLR camera (Nikon D200; Nikon, Melville, NY, USA).
Observers were masked to mouse genotypes while evaluating clinical phenotypes. Phenotypic
evaluation included considerations for iris structure, pupillary abnormalities, cataracts and the
overall dimensions of the anterior chamber.
Ocular biometry
Ocular biometry was performed using optical coherence tomography or a digital Vernier cali-
per. Envisu R4300 spectral-domain optical coherence tomography (SD-OCT, Leica/Bioptigen
Inc., Research Triangle Park, NC, USA) was employed to measure the ocular axial length, reti-
nal thickness, vitreous chamber depth (VCD) and anterior chamber depth (ACD) as previously
described with minor modifications [25]. Briefly, mice were anesthetized with ketamine/xyla-
zine (100 mg/kg and 5mg/kg, respectively; intraperitoneal) and their eyes dilated before placing
the animal in a cylindrical holder. The eye was hydrated with Genteal (Alcon, Fort Worth, TX,
USA) and positioned in front of the OCT light source. Correct alignment of the eye was
achieved by placing the Purkinje image in the center of the pupil. The images were acquired in
rectangular volume and radial volume scans to capture the retinal thickness and axial length
measurements, respectively. The axial length was calculated by measuring the distance from the
corneal surface to the RPE/choroid interface. The distance between the innermost layer of the
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retina and the lens was used to calculate the VCD. ACD is the distance between the innermost
cornea layer and lens. For biometric analyses performed before eye opening (before P13), mice
were anesthetized and their eyelid carefully slit open using fine scissors. Thereafter, the eye was
gently protruded using a Q-tip and aligned to the light source as described above. Digital Ver-
nier caliper (Fowler Ultra-Cal Mark III) was used to measure the equatorial diameter as
described previously [36]. Eyes were enucleated and magnified under a dissecting scope. The
Vernier caliper was positioned along the nasal and temporal plane at a point of maximum diam-
eter. Ocular biometry was performed on both the left and right eyes of a given mouse. S1–S3
Tables summarize the details about sample size, body weight, and biometric measurements of
mice in each experimental cohort. To minimize the possible effect of body weight on ocular
size, we ensured that body weight of littermates was within a narrow range in each of the com-
parative groups.
Refraction measurement
Ocular refractions were acquired using an automated infrared photorefractor as described pre-
viously with some minor modifications [28]. Refraction was measured following treatment of
mouse eyes with cyclopentolate (Alcon, Fort Worth, Tx, USA) to temporarily paralyze the cili-
ary body (cycloplegic refraction). Mice were placed on a pedestal with their eyes facing the
photorefractor. The photorefractor was maintained at a distance and maneuvered to obtain a
clear focused image of the eye. The photorefractor registers a successful refraction measure-
ment only when the Purkinje image is positioned in the center of the pupil as detected and
marked by a green LED flash. Centering of the Purkinje image ensures the infrared rays pass
along the optical axis. In a typical recording, around 30–50 refraction measurements are
acquired, which are then used to calculate the mean OD. Refraction measurements were per-
formed on both the left and right eyes of a given mouse. A total of at least 6 eyes per experi-
mental group were used for refraction measurements and experimental mice of both sexes
were used for refraction measurements.
Quantitative real-time polymerase chain reaction (qRT-PCR)
Eyes were enucleated and retinas were immediately dissected. Total RNA was isolated from
retina using Qiagen RNeasy Mini Kit with on-column DNase I treatment (Qiagen, Valencia,
CA, USA) and reverse transcribed using iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA,
USA). qPCR was performed on a Bio-Rad C1000 Thermal Cycler/CF96 Real-Time System
using SsoAdvancedTM SYBR Green1 Supermix (Bio-Rad, Hercules, CA, USA), and primer
sets listed in S5 Table. Briefly, 15ng of cDNA and 0.25 μM primers were used per reaction in a
final volume of 10 μl of Supermix. Each cycle consisted of denaturation at 95˚C for 5s, followed
by annealing and extension at 60˚C for 25s. Each reaction was run as technical duplicates and
a minimum of 4 biological replicates was used per group. The relative expression level of each
gene was normalized to housekeeping genes (Actb, Hprt1, and/or Mapk1) and analyzed using
the CFX manager software (Bio-Rad, Hercules, CA, USA).
Lineage tracing and Mu¨ller glia endfeet assessment using the Prss56Cre;
R26tdTomato reporter mice
Prss56Cre mice were bred to tdTomato reporter mice (R26tdTomato) to generate offsprings with
one copy of each of tdTomato and Cre recombinase under the control of the Prss56 promoter.
The offsprings (heterozygous control Prss56Cre/+; R26tdTomato) were utilized for Prss56 lineage
tracing and expression analysis. The eyes were enucleated at both embryonic and postnatal time
points. The eyes were processed, sectioned and visualized for tdTomato fluorescence as described
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below. To assess tdTomato expression (S3 Fig) and organization of Mu¨ller glial endfeet (Fig 7G
and 7H) in a Prss56 mutant context (homozygous mutant), we designed our breeding strategy
such that Prss56 mutant mice carried a single copy of both tdTomato and Prss56Cre (similar to
control mice) and a copy of the Prss56glcr4 allele (Prss56Cre/glcr4; R26tdTomato). Our design ensured
uniform copy number of tdTomato and Prss56Cre, allowing a direct comparison of tdTomato
expressing cells between Prss56 mutant and heterozygous control eyes.
Immunofluorescence
Eyes were enucleated and immersion-fixed in 4% paraformaldehyde (PFA) in phosphate buff-
ered saline (PBS) overnight at 4˚C, cryoprotected in 20% sucrose in PBS, and embedded in
Optimal Cutting Temperature (O.C.T.) compound (Tissue-Tek; Sakura Finetek, Torrance,
CA, USA). Twelve micron cryosections were immunolabeled with anti-Sox2 (1:500 dilution,
goat, cat#AF2018, R&D systems, MN, USA), or anti-PKCα (1:250, rabbit, P4334, Sigma,
St. Louis, MO, USA) or anti-Vimentin (1:100 dilution, mouse IgM, clone 40E-C, IA, DSHB,
USA), antibodies in PBS containing 10% normal donkey serum, 0.1% TritonX-100 (PBS-T).
Immunolabeling was visualized using AlexaFluor 594 or 488 conjugated secondary antibodies
raised in donkey (1:500, Life Technologies, Carlsbad, CA, USA) in PBS-T. Slides were
mounted in Mowiol containing DAPI (2 μg/ml).
In situ hybridization
Mice were transcardially perfused with ice-cold RNase-free PBS followed by 4% PFA (in
RNase-free PBS). Enucleated eyes were post-fixed in RNAse-free 4% PFA, cryoprotected in
20% sucrose, and embedded in OCT and sectioned within 24 hours for in situ hybridization.
QuantiGene View RNA (Affymetrix, Santa Clara, CA, USA) in situ hybridization assay was
performed according to the manufacturer protocol. Briefly, 12μm cryosections were fixed
overnight in 4% PFA, dehydrated through a graded series of ethanol, were subjected to 2X pro-
tease digestion for 10 minutes, postfixed with 4% PFA and hybridized with probe sets against
the gene of interest for 3 hours at 40˚C using a ThermoBrite system (Abbott Molecular, Des
Plaines, IL, USA). Cryosections were then washed and subject to signal amplification and
detection using fast red substrate, counterstained and mounted for subsequent imaging. For
dual fluorescent in situ hybridization, Digoxigenin- and Fluorescein-labeled riboprobes were
synthesized from full-length cDNA clones (MGC Mouse glutamine synthetase cDNA Clone
Id:4224865). The hybridized mRNA was detected using the TSA-FITC/ TSA-CY5 Tyramide
Signal Amplification System (PerkinElmer, Waltham, MA, USA).
Tamoxifen injection
Tamoxifen (T-5648, Sigma, St. Louis, MO, USA) was dissolved in ethanol (200mg/ml) and
diluted in corn oil (final concentration of 20mg/ml tamoxifen). Each experimental mouse
received a single intraperitoneal injection of tamoxifen (0.6 mg or 30 μl of tamoxifen solution/
mouse for P6 and P8 pups and 0.8 mg or 40 μl for P13 and P18 mice).
Histology
Mice were euthanized and eyes enucleated and immediately immersed in cold fixative (1%
PFA, 2% glutaraldehyde, and 0.1 M cacodylate buffer) for 24 hours, after which they were
transferred to cold 0.1 M cacodylate buffer solution for an additional 24 hours. Samples were
embedded in glycol methacrylate, and serial sagittal sections (2μm) passing through the optic
nerve were cut and stained with hematoxylin and eosin (H&E).
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Retinal whole mount preparation and endfeet assessment
Retina was dissected from Prss56Cre/+; R26tdTomato (control) or Prss56Cre/glcr4; R26tdTomato
(mutant) mice and four radial incisions made and mounted on a slide. tdTomato positive ter-
minal endings of Mu¨ller glia projection (endfeet) were visualized and images captured using a
Confocal mircroscope (Carl Zeiss LSM700). Eight equivalent areas of the retina were consis-
tently selected for each whole mount. Mu¨ller glia endfeet were classified into two groups based
on their morphology: 1) Mu¨ller glia endfeet showing simple cohesive arrangement and occu-
pying smaller area of the retina. 2) Mu¨ller glia endfeet exhibiting more spread-out morphology
and covering a larger area, suggestive of increased branching and elaboration. Two indepen-
dent observers masked to genotypes manually quantified the relative distribution of the two
types of endfeet.
Retinal cell suspension
Eyes were enucleated and retina was isolated and minced in DMEM (Dubelcco’s Modified
Eagles Medium, Gibco-Invitrogen Corporation, Carlsbad, CA, USA). Retina was then dissoci-
ated in 15IU papain (Worthington Biochemicals Freehold, NJ, USA) and 20μg/ml DNase I
(Roche Applied Science, Mannheim, Germany) for 30 minutes at 37˚C, gently triturated using
a glass Pasteur pipet and passed through a 40 μm cell strainer. Tissue trapped by the strainer
was digested with 1 mg/ml collagenase type I (Worthington Biochemicals Freehold, NJ, USA)
and 15 μg/ml DNAse I (Roche Applied Science, Mannheim, Germany) for 30 min at 37˚C.
Flow-through was mixed with DMEM with 10% fetal bovine serum (FBS, Gibco-Invitrogen
Corporation, Carlsbad, CA, USA) and washed 2X (300g for 2 minutes at RT). The retinal cell
suspension was used for flow cytometry.
Flow cytometry
Retinal cell suspension was fixed in 4% PFA and subjected to indirect immunolabeling using
anti-GS (mouse, 1:500, MAB302, EMD Millipore, Billerica, MA, USA) or anti-Rhodopsin
(mouse, 1:1000, MAB5336, EMD Millipore, Billerica, MA, USA) and fluorochrome labeled
secondary antibodies (AlexaFluor 488 conjugated secondary antibodies raised in donkey,
1:500, Life Technologies, Carlsbad, CA, USA) in 10% NDS/PBS containing 0.1% Triton X-100
at 4˚C. Flow cytometry of immunolabeled cell suspension was performed using a BD™ LSRII
Fortessa flow cytometer and FACS Diva Software (BD Biosciences, San Jose, CA). Retinal cell
suspension from Prss56Cre/+; R26TdTomato/+ mice incubated with AlexaFluor 488-conjugated
secondary antibody were used as negative controls to establish gating parameters.
Microscopy
Bright-field images were captured using AxioVision software and an AxioImager M1 micro-
scope equipped with an AxioCam ICc3 digital camera (Carl ZeissMicroscopy, LLC, Germany).
Fluorescent images were acquired using AxioImager M1 microscope equipped with an MRm
digital camera and AxioVision software, with an LSM700 confocal microscope and a Zen soft-
ware (Carl Zeiss Microscopy, LLC, Germany). Amira software was used for 3D visualization
and analysis.
Human ocular biometry
We obtained illustrative biometric data from a nanophthalmic patient affected with a homozy-
gous missense variant (p.G320R) in PRSS56 previously identified by one of the authors (ACO)
[38], and also a representative normal volunteer for comparison. Approval for this study was
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obtained from the Research Ethics Board of the Nova Scotia Health Authority, Halifax, Nova
Scotia, Canada. In brief, ocular dimensions measured via ultrasound biomicroscopy A- and B-
scan techniques revealed a very small globe bilaterally featuring crystalline lenses that were
normally positioned, but large in size relative to that of the eye. The choroid was also observed
to be diffusely thickened.
Statistical analysis
Statistical comparisons between control and mutant samples were performed by a two-tailed
unpaired Student’s t-test using Prism version 6.0f software. p values of<0.05 were considered
significant. Power for a two-tailed two-sample t-tests was calculated using a range of means
and standard deviation values of axial length that could be reasonably expected based on pub-
lished data and our initial assessment [26]. Although the difference between the two group
means and within-group standard deviation are statistically independent parameters, in many
biological data sets they show various levels of collinearity. Therefore, for small, medium and
large μ1- μ 2 values, we based our power calculation on correspondingly increasing expecta-
tions of SD. The detection of differences with 80% power is possible in these scenarios with
sample sizes 7. For example, with respect to axial length, a mean difference of 50 μm, SD = ±
30, the effect size is 1.67 requiring a sample size of 6. Where logistically possible, and partly as
a precaution against the possibility of some failed experiments, we collected data from more
samples. Number of eyes, mean and standard deviation of all measurements in each group are
presented in S1–S3 Tables.
Supporting information
S1 Fig. Ocular dimensions of Prss56+/- and Prss56+/+ mice are indistinguishable and signifi-
cantly different from those of Prss56-/- mice. (A, B) Histograms showing that ocular axial
length (A) and retinal thickness (B) are indistinguishable in Prss56+/- and Prss56+/+ mice at 3
months of age. (C) Representative images of enucleated eyes showing a modestly reduced size
in Prss56-/- compared to Prss56+/- mice (shown are P15 eyes). (D) Representative optical coher-
ence tomography images of 2 months old eyes. (E-H) Histograms showing reduced ocular
axial length (E), increased retinal thickness (F), increased anterior chamber depth (ACD),
decreased vitreous chamber depth (VCD) (G) in Prss56-/- eyes compared to Prss56+/- mice at 2
months of age. (H) Lens thickness was indistinguishable between Prss56-/- and Prss56+/- eyes.
Data are presented as mean ± SD, p<0.001, t-test. In (A) N = 6 and 4 for Prss56+/- and
Prss56+/+, respectively; in (E-H) N = 10 and 9 for Prss56+/- and Prss56-/-, respectively.
(TIF)
S2 Fig. Prss56 ocular expression is restricted to the retina. (A-D) Representative images of
Prss56Cre/+;R26tdTomato/+ and Prss56+/+;R26tdTomato/+ ocular sections showing that tdTomato
labeling (in red, reporting Prss56 expression) is restricted to the retina in Prss56Cre/+;R26tdTo-
mato/+ mice. (B) tdTomato was not detected in the absence of Cre expression (Prss56+/+;R26tdTo-
mato/+). tdTomato-labeled cells were enriched in the peripheral region and relatively sparser in
the central region of the retina (A, C, the peripheral and central regions of the retina are ori-
ented left to right). (C, D) tdTomato expression was not detected in the iridocorneal angle, cili-
ary body (CB), cornea, lens, sclera, choroid or retinal pigment epithelium (RPE). Scale
bars = 100μm.
(TIF)
S3 Fig. Prss56 expression in Prss56 mutant and control retina. (A) Representative image of
P20 Prss56Cre/+;R26tdTomato/+ retinal sections immunolabeled for the glial cell marker vimentin,
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showing colocalization of tdTomato and vimentin (arrows). (B) Detection of Prss56 mRNA
expression at P10 and P15 using QuantiGene View RNA in situ hybridization. Top panel: A
representative image of P10 retina showing Prss56 expression predominantly in the peripheral
region of the retina. At P15, increased Prss56 expression was detected in the inner nuclear
layer of the retina in mutant mice compared to their wild-type littermates. (C) Representative
P30 eye sections showing an increased number of tdTomato positive cells in a mutant
Prss56Cre/glcr4;R26tdTomato/+ retina compared to control Prss56Cre/+;R26tdTomato/+ retina. Of note,
while tdTomato expression is enriched in the peripheral region of the retina in control
Prss56Cre/+;R26tdTomato/+ eyes, tdTomato distribution is more uniform in Prss56 mutant retina
(Prss56Cre/glcr4). (D) Representative images of retinal sections showing absence of immunola-
beling when using rabbit or goat IgG isotypes as negative controls. CB, ciliary body; GCL, gan-
glionic cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; P, postnatal day. Scale
bars; 500 μm (A), 100 μm for P10 and 50 μm for P15 (B), and 50 μm (C).
(TIF)
S4 Fig. Generation of conditional Prss56 mutant mice. (A) Prss56 alleles and targeting con-
struct. Top: Wild-type Prss56 allele (exons indicated as solid black rectangles). Middle: Target-
ing vector containing 2 LoxP sites (black triangles) flanking Prss56 exons 3 and 4 and a
Neomycin selection cassette (Neo) flanked by 2 Frt sites (green triangles). Insertion of the tar-
geting vector by homologous recombination in embryonic stem (ES) cells yielded Prss56F_Neo.
Prss56F_Neo ES cells were used to generate chimeric mice that were bred to mice expressing
flippase for excision of the Neomycin selection cassette to generate mice carrying the condi-
tional Prss56 mutant allele (Prss56F). The Prss56F allele expresses normally and behaves as the
wild-type Prss56 allele in the absence of Cre recombinase activity. Bottom: Cre recombinase
activation causes deletion of exons 3 and 4 resulting in a frameshift mutation and premature
stop codon, rendering the Prss56 gene inactive. (B-C) Prss56 gene targeting was confirmed by
Southern hybridization (not shown) and PCR. PCR analyses using various primer combina-
tions (gray triangles in A) are shown. PCR amplification of DNA from wild-type mice (lane 1),
mice heterozygous or homozygous for the Prss56 conditional allele (Prss56F/+, lane 2; and
Prss56F/F, lane 3), and mice homozygous for the Prss56 conditional allele in presence of a ubiq-
uitous Sox2-Cre recombinase (lane 4). PCR reactions using the F1R1 primer pair gives a prod-
uct that is about 34 bp longer in mice carrying the Prss56F allele compared to wild-type mice.
In the presence of Cre recombinase, deletion of exon 3 and 4 from the Prss56F allele gives no
PCR product. PCR reactions using the F2R2 primer pair lead to product sizes of 280bp for the
wild-type allele and 350bp for the Prss56F allele and no PCR product for the Prss56F allele fol-
lowing Cre activation. PCR reactions using the primer pair F1R2 give rise to product sizes of
820bp and 920bp for the wild-type and Prss56F alleles, respectively. Additionally, primer pair
F1R2 confirmed excision of exons 3 and 4 from the Prss56F allele following CRE activation as
shown by the presence of a shorter PCR product size of 290bp.
(TIF)
S5 Fig. Ubiquitous Sox2-Cre-mediated conditional ablation of Prss56 recapitulates the
ocular phenotype observed in Prss56-/- mice. (A) Prss56F/F mice were bred to mice ubiq-
uitously expressing Cre recombinase under the control of the Sox2 promoter (Sox2-Cre).
Representative images of slit lamp examination by broad-beam illumination of Prss56F/+;
Sox2-Cre and Prss56F/F;Sox2-Cre to assess ocular structures including the iris, pupil, and
lens at 2 months of age. Prss56F/F;Sox2-Cre eyes were indistinguishable from control
Prss56F/+;Sox2-Cre eyes and did not exhibit any obvious structural abnormalities. (B, C)
Prss56F/F;Sox2-Cre eyes exhibit a significant reduction in axial length (B) and equatorial
diameter (C) compared to control Prss56F/+;Sox2-Cre eyes. Values are presented as
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mean ± SD;  p<0.05,  p<0.01,  p<0.001, t-test. N 4 per genotype.
(TIF)
S6 Fig. Increase in ocular anterior chamber depth following Prss56 ablation at P18. (A)
Ocular biometry following tamoxifen injection at P18 shows that lens diameter is indistin-
guishable between Prss56F/F;Ubc-CreERT2 and control Prss56F/+;Ubc-CreERT2 mice. (B) Prss56F/
F;Ubc-CreERT2 mice display a slight increase in ACD compared to the control group. Values are
presented as mean ± SD. For comparison between mutant and control eyes,  p<0.05,
p<0.01,  p<0.001, t-test.
(TIF)
S7 Fig. The ocular dimensions of Egr1+/-;Prss56+/- mice are indistinguishable from that of
Egr1+/+;Prss56+/+. (A-D) Histograms showing that ocular axial length (A), retinal thickness
(B), anterior chamber depth (ACD), vitreous chamber depth (VCD) (C), and lens thickness
(D) are indistinguishable in Egr1+/-;Prss56+/- and Egr1+/+;Prss56+/+ mice at P30. Values are pre-
sented as mean ± SD.
(TIF)
S1 Table. Summary of ocular measurements in Prss56 mutant mice across ages.
(DOCX)
S2 Table. Summary of ocular measurements in Prss56 conditional mutant mice.
(DOCX)
S3 Table. Summary of ocular measurements of Prss56/Egr1 genetic interaction study.
(DOCX)
S4 Table. List of genotyping primers.
(DOCX)
S5 Table. List of qPCR primers.
(DOCX)
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